Company news

ImmuneOnco announces acceptance of patent application by China SIPO on a novel recombinant chimeric PD-1 receptor (CPR)

2016-1-13 0:00:00Click:880

    On January 13 of 2016, ImmuneOnco announced acceptance of the patent application by China SIPO on a novel engineered recombinant chimeric PD-1 receptor (CPR). Upon ligation of the CPR with either PD-L1-expressing tumor cell line or PD-1-specific antibody such as Nivolumab, it delivers a stimulating signal that drives CPR-expressing Jurkat cells to secret large amount of IL-2. “We believe this chimeric PD-1 receptor will be useful both in development of therapeutic TANK cell line, and in screening of PD-1/PD-L1 antibody as drug candidates”, commented Dr. Wenzhi Tian, Founder and Chairman of ImmuneOnco.